The IRE Resource Center is a major research library containing more than 23,250 investigative stories — both print and broadcast. These stories are searchable online or by contacting the Resource Center directly (573-882-3364 or rescntr@ire.org) where a researcher can help you pinpoint what you need. Browse or search the tipsheet section of our library below. Stories are not available for download but can be easily ordered by contacting the Resource Center:
Search results for "FDA regulatory letters" ...
-
Free Rein for Drug Ads?
The Food and Drug Administration has been slow to stop an alarming number of inaccurate drug advertisements, leaving consumers and the doctors that actually prescribe the medicines vulnerable to false or misleading messages. The investigation found ads that minimized prescription drug risks, exaggerated efficacy, made false claims of superiority over competing products, promoted unapproved uses of an approved drug, or promoted use of a drug still in the experimental stage. Such drug ads may contribute to excessive or inappropriate prescribing and to soaring prescription drug spending.
Tags: FDA; Food and Drug Administration; drug advertisements; consumers; FDA Center for Drug Evaluation and Research; Freedom of Information Electronic Reading Room; FDA regulatory letters; prescription drug risks; Tamiflu; drugmakers; corrective ads; Department of Health and Human Services; General Accounting Office; Fosamax; Ambien; AARP; Prilosec